Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2019 2
2020 3
2021 3
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Nanda VGY, Peng W, Hwu P, Davies MA, Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA, Croce CM, Mancini R, Spranger S, Gajewski TF, Wang Y, Ferrone S, Vanpouille-Box C, Wennerberg E, Pilones KA, Formenti SC, Demaria S, Tang H, Wang Y, Fu YX, Dummer R, Puzanov I, Tarhini A, Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sanders C, Kirkwood JM, Chen THT, Maurer M, Korman AJ, Zarour HM, Stroncek DF, Huber V, Rivoltini L, Thurin M, Rau T, Lugli A, Pagès F, Camarero J, Sancho A, Jommi C, de Coaña YP, Wolodarski M, Yoshimoto Y, Gentilcore G, Poschke I, Masucci GV, Hansson J, Kiessling R, Scognamiglio G, Sabbatino F, Marino FZ, Anniciello AM, Cantile M, Cerrone M, Scala S, D’alterio C, Ianaro A, Cirin G, Liguori G, Bott G, Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Testori A, Lorigan P, Sosman JA, Flaherty KT, Yue H, Coleman S, Caro I, Hauschild A, McArthur GA, Sznol M, Callahan MK, Kluger H, Postow MA, Gordan R, Segal NH, Rizvi NA, Lesokhin A, Atkins MB, Burke MM, Ralabate A, Rivera A, Kronenberg SA, Agunwamba B, Ruisi M, Horak C, Jiang J, Wolchok J, Ascierto PA, Liszkay G, Maio M, Mandalà M, Demidov L, Stoyakovskiy D, Thomas L, de la Cruz-Me… See abstract for full author list ➔ Nanda VGY, et al. J Transl Med. 2016 Jul 25;14(1):65. doi: 10.1186/s12967-016-0791-2. J Transl Med. 2016. PMID: 27461275 Free PMC article.
Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandala, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. ...Pitt, Nadege V …
Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandala, Lev Demidov, Daniil Stoyakovskiy, Luc Thom …
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Maiorano BA, Di Maio M, Cerbone L, Maiello E, Procopio G, Roviello G; MeetURO Group. Maiorano BA, et al. JAMA Netw Open. 2024 Mar 4;7(3):e241215. doi: 10.1001/jamanetworkopen.2024.1215. JAMA Netw Open. 2024. PMID: 38446479 Free PMC article.

The ORR was 13.8% to 78.6% in patients with PD-L1-positive tumors and 5.1% to 63.2% in patients with PD-L1-negative tumors, with an association between PD-L1 status and ORR favoring patients with PD-L1-positive tumors (OR, 1.94; 95% CI, 1.47-2.56; P < .001). Median OS r

…
The ORR was 13.8% to 78.6% in patients with PD-L1-positive tumors and 5.1% to 63.2% in patients with PD-L1-negative tumors, with an associat …
Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment.
Raffone A, Travaglino A, Saccone G, Di Maio A, Mollo A, Mascolo M, De Rosa R, De Placido G, Insabato L, Zullo F. Raffone A, et al. Gynecol Endocrinol. 2019 Nov;35(11):932-937. doi: 10.1080/09513590.2019.1624716. Epub 2019 Jun 5. Gynecol Endocrinol. 2019. PMID: 31165649 Review.

The association of diabetes mellitus with treatment failure was assessed by using odds ratio (OR). A p-value < .05 was considered significant. The risk of publication bias was assessed by using a funnel plot. ...Overall, diabetes mellitus was not associated with outcome

…

The association of diabetes mellitus with treatment failure was assessed by using odds ratio (OR). A p-value < .05 was considered

…
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
Tabbò F, Muscarella LA, Gobbini E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, Gregorc V, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, Cortinovis D, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, Graziano P, Novello S, Righi L. Tabbò F, et al. Eur J Cancer. 2022 Oct;174:200-211. doi: 10.1016/j.ejca.2022.07.026. Epub 2022 Aug 28. Eur J Cancer. 2022. PMID: 36044814
The presence of V1 variant was associated with progression-free survival (PFS) improvement when crizotinib was used (p = 0.0073), while it did not affect cumulative PFS to multiple ALKi. ...
The presence of V1 variant was associated with progression-free survival (PFS) improvement when crizotinib was used (p = 0.0073), whi …
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.
Facchinetti F, Di Maio M, Tiseo M. Facchinetti F, et al. Cancers (Basel). 2020 Sep 16;12(9):2645. doi: 10.3390/cancers12092645. Cancers (Basel). 2020. PMID: 32947924 Free PMC article. Review.

Adding a PD-1/PD-L1 ICI to chemotherapy led to a significant benefit in OS [hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.68-0.85, p < 0.00001), PFS [HR 0.75, 95% CI 0.68-0.84, p < 0.00001] and ORR [odds ratio 1.28, 95% CI 1.04-1.57, p = 0.02].

…
Adding a PD-1/PD-L1 ICI to chemotherapy led to a significant benefit in OS [hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.68-0.85, …
Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2.
De Maio F, Palmieri V, Babini G, Augello A, Palucci I, Perini G, Salustri A, Spilman P, De Spirito M, Sanguinetti M, Delogu G, Rizzi LG, Cesareo G, Soon-Shiong P, Sali M, Papi M. De Maio F, et al. iScience. 2021 Jul 23;24(7):102788. doi: 10.1016/j.isci.2021.102788. Epub 2021 Jun 25. iScience. 2021. PMID: 34222841 Free PMC article.
Italian natural history museums on the verge of collapse?
Andreone F, Bartolozzi L, Boano G, Boero F, Bologna MA, Bon M, Bressi N, Capula M, Casale A, Casiraghi M, Chiozzi G, Delfino M, Doria G, Durante A, Ferrari M, Gippoliti S, Lanzinger M, Latella L, Maio N, Marangoni C, Mazzotti S, Minelli A, Muscio G, Nicolosi P, Pievani T, Razzetti E, Sabella G, Valle M, Vomero V, Zilli A. Andreone F, et al. Zookeys. 2014 Nov 24;(456):139-46. doi: 10.3897/zookeys.456.8862. eCollection 2014. Zookeys. 2014. PMID: 25709525 Free PMC article.
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves.
Mariniello A, Bironzo P, Pisano C, De Filippis M, Persano I, Olmetto E, Caramello V, Boccuzzi A, Capelletto E, Passiglia F, Di Maio M, Novello S. Mariniello A, et al. JCO Oncol Pract. 2021 Dec;17(12):e1887-e1894. doi: 10.1200/OP.21.00098. Epub 2021 Jul 6. JCO Oncol Pract. 2021. PMID: 34228511 Free PMC article.
RESULTS: C19-CP in the second wave exceeded those in the first wave despite the nonsignificant difference (39 of 576 v 8 of 163; P = .5). Compared with nononcological patients, C19-CP were older (median age 70 years [interquartile range 61-77] v 60 years [interquartile ran …
RESULTS: C19-CP in the second wave exceeded those in the first wave despite the nonsignificant difference (39 of 576 v 8 of 163; P = …
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Verzoni E, Clemente A, Guadalupi V, Signorelli D, Tiseo M, Giusti R, Filetti M, Di Napoli M, Calvetti L, Cappetta A, Ermacora P, Zara D, Barbieri F, Baldessari C, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Maruzzo M, Rossi E, Grossi F, Casadei C, Cortellini A, Verderame F, Montesarchio V, Rizzo M, Mencoboni M, Zustovich F, Fratino L, Cinieri S, Negrini G, Banzi M, Sorarù M, Zucali PA, Lacidogna G, Russo A, Battelli N, Fornarini G, Mucciarini C, Bracarda S, Bonetti A, Pezzuolo D, Longo L, Sartori D, Iannopollo M, Cavanna L, Meriggi F, Tassinari D, Corbo C, Gernone A, Prati V, Carnio S, Giordano P, Dicorato AM, Verusio C, Atzori F, Carrozza F, Gori S, Castro A, Pilotto S, Vaccaro V, Garzoli E, Di Costanzo F, Maiello E, Labianca R, Pinto C, Tognetto M, Buti S. Bersanelli M, et al. Ther Adv Med Oncol. 2020 Nov 2;12:1758835920968463. doi: 10.1177/1758835920968463. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33224275 Free PMC article.

The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated (p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all con

…
The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated ( …
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
Zichi C, Paratore C, Gargiulo P, Mariniello A, Reale ML, Audisio M, Bungaro M, Caglio A, Gamba T, Perrone F, Di Maio M. Zichi C, et al. Eur J Cancer. 2021 May;149:49-60. doi: 10.1016/j.ejca.2021.03.007. Epub 2021 Apr 3. Eur J Cancer. 2021. PMID: 33823362 Free article.
The proportion of trials with MPEs increased over time, from 6% in 2017 to 20% in 2020 (p = 0.025). MPEs were adopted in 16% of for-profit trials versus 4% of non-profit trials (p = 0.006). The proportion of trials adopting MPEs was particularly high with immunother …
The proportion of trials with MPEs increased over time, from 6% in 2017 to 20% in 2020 (p = 0.025). MPEs were adopted in 16% of for-p …
12 results